| Views | |
|---|---|
| Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study | 245 |
| January 2024 | February 2024 | March 2024 | April 2024 | May 2024 | June 2024 | July 2024 | |
|---|---|---|---|---|---|---|---|
| Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study | 0 | 0 | 199 | 11 | 12 | 16 | 7 |
| Views |
|---|
| Views | |
|---|---|
| United States | 201 |
| China | 23 |
| Netherlands | 6 |
| Canada | 3 |
| Spain | 2 |
| Panama | 1 |
| Russia | 1 |
| Views | |
|---|---|
| Kansas City | 134 |
| Menlo Park | 16 |
| Garden City | 10 |
| Ann Arbor | 9 |
| Houston | 8 |
| Shanghai | 7 |
| Guangzhou | 6 |
| Oakland | 6 |
| Boardman | 5 |
| San Diego | 4 |